10-Q: Alnylam Pharmaceuticals Reports Strong Q2 2026 Financials

Alnylam Pharmaceuticals announced robust Q2 2026 results, driven by significant growth in AMVUTTRA sales and increased royalty revenue.

Summary

• Alnylam Pharmaceuticals reported total revenues of $1.29 billion for Q2 2026, a 67% increase year-over-year, primarily driven by strong AMVUTTRA sales.
• Net product revenues reached $1.17 billion, up 74% from Q2 2025, with AMVUTTRA sales alone totaling $1.01 billion.
• Net income for the quarter was $164.5 million, a significant turnaround from a net loss of $72.2 million in Q2 2025.
• Research and development expenses increased by 28% to $413.1 million, reflecting ongoing investment in late-stage clinical trials.
• Selling, general, and administrative expenses rose by 8% to $347.9 million, attributed to increased marketing for AMVUTTRA.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, a return to profitability, and continued investment in a promising pipeline, despite some product revenue declines and increased R&D spending.

Positives

• Total revenues increased by 67% to $1.29 billion in Q2 2026 compared to Q2 2025.
• Net product revenues grew by 74% to $1.17 billion, largely due to AMVUTTRA's strong performance.
• AMVUTTRA sales reached $1.01 billion in Q2 2026, a 106% increase year-over-year.
• The company achieved net income of $164.5 million in Q2 2026, compared to a net loss of $72.2 million in the prior year period.
• Royalty revenue increased by 79% to $71.7 million, primarily from Leqvio sales.
• Cash, cash equivalents, and marketable securities stood at $3.31 billion as of June 30, 2026, indicating a strong liquidity position.

Negatives

• ONPATTRO net product revenues decreased by 65% to $18.5 million in Q2 2026 compared to Q2 2025.
• Net revenues from collaborations decreased by 23% to $47.2 million, mainly due to lower revenue from the Regeneron Collaboration.
• Cost of goods sold as a percentage of net product revenues increased to 25.4% from 21.1% in the prior year period, driven by higher royalty rates on AMVUTTRA sales.
• Stock-based compensation expense decreased in R&D and SG&A, but overall R&D expenses increased due to higher clinical trial costs.

Risks

• The company's business is dependent on the sustained and growing revenue from AMVUTTRA sales.
• Competition from existing and new therapies for ATTR amyloidosis, including pill-formulated drugs with lower list prices, could impact AMVUTTRA's market share.
• Delays in patient enrollment or unforeseen drop-out rates in clinical trials could increase costs and lengthen development timelines.
• Failure to obtain or maintain regulatory approvals for product candidates could prevent commercialization.
• Reliance on third-party manufacturers for product supply carries risks of delays or disruptions.
• Potential for intellectual property litigation and challenges to patent rights could adversely affect the business.
• Changes in healthcare laws, regulations, pricing, and reimbursement policies could negatively impact revenues.
• The company may require additional funding in the future to support its ongoing research, development, and commercialization activities.

Future Outlook

The company expects to continue investing significantly in research and development to advance its RNAi platform and clinical pipeline, aiming to achieve its Alnylam 2030 strategy goals, which include expanding to 10 tissue types, having over 40 clinical programs, delivering at least two new transformative medicines beyond TTR with blockbuster potential, investing approximately 30% of revenues in non-GAAP R&D, and achieving a 25%+ total revenue compound annual growth rate with a 30% non-GAAP operating margin through 2030. The company anticipates royalty revenue will increase in 2026 due to higher Leqvio sales.

Management Comments

• The company achieved profitability for the first time in 2025 and expects to fund operations primarily from product revenues, supplemented by collaboration and royalty revenue.
• The company expects to continue investing significantly in research and development to advance its RNAi platform and clinical pipeline.
• The company believes nucresiran has the potential to become a leading therapy for ATTR amyloidosis and significantly improve gross margins on product sales and operating income margin.

Industry Context

StockSavvy.ai notes that Alnylam's strong performance in Q2 2026, particularly with AMVUTTRA, aligns with the growing market for RNAi therapeutics. The company's continued investment in R&D and expansion of its pipeline demonstrate a strategic focus on innovation within the competitive biopharmaceutical landscape.

Legal Proceedings

• The Board of Regents of the University of Texas System filed a lawsuit alleging infringement of U.S. Patent No. 8,895,717 by ONPATTRO; the case was transferred to the U.S. District Court for the District of Massachusetts.
• Alnylam and collaborators filed a patent infringement lawsuit against Cipla USA Inc. and Cipla Ltd. regarding Cipla's ANDA for a generic version of Leqvio.
• The company received a subpoena from the U.S. Attorneys Office for the District of Massachusetts seeking documents pertaining to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI.

Stakeholder Impact

• Shareholders are likely to see positive impact from the strong revenue growth and return to profitability.
• Patients may benefit from continued access to and development of RNAi therapeutics for various diseases.
• Collaborators may see increased royalty and milestone payments due to strong product sales.

Next Steps

• Continue global commercial launch of AMVUTTRA for ATTR-CM.
• Advance late-stage clinical programs, including TRITON-PN and TRITON-CM for nucresiran, and ZENITH for zilebesiran.
• Progress early-stage clinical pipeline and efforts to deliver RNAi therapeutics to additional tissues and disease areas.
• Selectively pursue complementary modalities through business development.

Key Dates

Recommendation

The company's strong Q2 2026 performance, driven by significant AMVUTTRA sales growth and a return to profitability, coupled with a robust pipeline and strategic investments in R&D, suggests continued positive momentum. The company's financial health and strategic positioning in the growing RNAi market warrant a buy recommendation.

Keywords

RNAi therapeutics, AMVUTTRA, ATTR amyloidosis, ONPATTRO, GIVLAARI, OXLUMO, zilebesiran, clinical trials